Therapure Biopharma Inc. signs fill/finish contract with Viron Therapeutics

TORONTO, ON Therapure Biopharma Inc. today announced a contract with Viron Therapeutics Inc., a London, Ontario based biotechnology company, to provide fill/finish services. Under the terms of the agreement, Therapure will provide two fill/finish runs for development-stage products in support of on-going clinical trials being conducted by Viron. Financial terms were not disclosed.

Viron Therapeutics is a clinical stage biopharmaceutical company pioneering the development of viral proteins to treat and prevent human inflammatory disorders. Viral proteins represent a revolutionary new class of drugs. By harnessing the evolutionary power of viruses and other pathogens to evade the human body's protective inflammatory response, Viron is able to identify and develop powerful protein therapeutics that have distinct advantages in potency and efficacy over conventional drug therapy.

“We are pleased to be selected by Viron to provide fill/finish services in support of their clinical program,” said Thomas Wellner, President and CEO of Therapure. “Therapure’s Health Canada licensed facility was designed and built to handle biologics and proteins. We look forward to expanding our relationship with Viron going forward” continued Mr. Wellner.

‘Viron is the first company to successfully advance a viral protein drug into human testing and we look forward to working with Therapure as we advance the clinical development of our products,’ said James Rae, Chief Executive Officer of Viron. ‘Our pipeline of additional compounds in preclinical development, combined with a robust discovery program, strongly positions the Company to be a leader in the discovery and commercialization of bio-therapeutics to treat inflammatory-based diseases. Therapure has demonstrated that they have the capabilities to support our commercialization efforts,’ Mr. Rae concluded.


Therapure Biopharma Inc. is an integrated biopharmaceutical company that develops, manufactures, purifies and packages therapeutic proteins. As a contract development and manufacturing organization (CDMO) Therapure Biopharma applies scientific, manufacturing, and downstream purification expertise with an intimate understanding of advanced biology, complex proteins, and regulatory processes to develop effective and innovative solutions to advance products from discovery to market for its clients. Therapure’s Health Canada licensed 130,000 sq. ft. facility, includes manufacturing, research and quality control laboratories and a cGMP warehouse, and is built to U.S. FDA, EMEA, MHRA and Health Canada standards for the aseptic handling and purification of proteins.

For more information, pl ease visit:

Company Contacts:

Thomas Wellner
President and CEO
Therapure Biopharma Inc.
+1 905 286-6204